Available online on 15.11.2020 at <http://ujpr.org>
Universal Journal of Pharmaceutical Research
 An International Peer Reviewed Journal

Open access to Pharmaceutical research
 This is an open access article distributed under the terms of the Creative Commons Attribution-Non
 Commercial Share Alike 4.0 License which permits unrestricted non commercial use,
 provided the original work is properly cited

Volume 5, Issue 5, 2020

Open Access

RESEARCH ARTICLE

VALIDATION OF HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF PSEUDOEPHEDRINE HCl, GUAIFENESIN, CHLORPHENIRAMINE MALEATE AND DEXTROMETHORPHAN HBr

Abdrhman Mahmoud Gamil¹, Mohammed Awadelkareem Hamad²

¹Department of Pharmaceutics, Al-Neelain University, Sudan.

²Department of Chemistry, Blue Nile Research Centre, Sudan.

ABSTRACT

Objectives: Pseudoephedrine HCl, Guaifenesin, Chlorpheniramine Maleate and Dextromethorphan HBr combination is a common combination cough syrup. Many validated methods are available for the determination of each compound alone and in combination with other drugs. The local pharmaceutical industry used to analyze such combination in individual assessment which is efforts and time consuming. The objective of this study is to validate a method for simultaneous determinations of the four compounds in one single injection.

Methods: HPLC method had been develop using detector at 210 nm, column C18 4.6 mm × 250 mm, 3µm and mobile phase of Potassium dihydrogen orthophosphate, acetonitrile, orthophosphoric acid, triethanolamine and water. The column oven temperature is 40°C, flow rate 0.8 ml/min and 60 minutes run time. The method had been validated according to the ICH guidelines with respect to method specificity, linearity and range, precision, accuracy and robustness. Limit of detection, quantitation limit and solution stability had been assessed.

Results: The average retention times the 4 compounds are 5.5, 12.63, 15.85, 50.44 minutes. The RSD% is less than 1%, the theoretical plates is more than 2000, the tailing factor is not more than 2 and the resolution between the peaks was found to be above 20. The Method showed an appropriate linearity having correlation coefficient r^2 0.9996 – 0.9998. The RSD% of results for two analysts in two different apparatus in two days was less than 2. The test solution is stable for 48 hours.

Conclusion: The method is simple and fulfilled all acceptable criteria for all validation parameters. The method is qualified enough to be used for routine analysis of products containing the four components.

Key words: Chemical method validation, chlorpheniramine, chromatographic system validation, dextromethorphan, guaifenesin, pseudoephedrine.

Article Info: Received 2 September 2020; Revised 3 October; Accepted 6 November, Available online 15 November 2020

Cite this article-

Gamil AM, Hamad MA. Validation of HPLC method for simultaneous determination of Pseudoephedrine HCl, Guaifenesin, Chlorpheniramine maleate and Dextromethorphan HBr. Universal Journal of Pharmaceutical Research 2020; 5(5):53-60.

DOI: <https://doi.org/10.22270/ujpr.v5i5.488>

Address for Correspondence:

Dr. Abdrhman Mahmoud Gamil, Associate Professor of Pharmaceutics, Al-Neelain University, Sudan, Tel: +249 912307227, E-mail: dean_pharmacy@neelain.edu.sd

INTRODUCTION

Validation of an analytical procedure is the process by which it is established, by laboratory studies, that the performance characteristics of the procedure meet the requirements for the intended analytical application¹. As per the ICH guidelines, the validation process of the method includes the specificity, linearity and range, precision, accuracy, solution stability, assay of pharmaceutical product and robustness².

Compounds structural formula:

Pseudoephedrine is a systemic decongestant, Quiafenesin is used as an expectorant and to liquefy the

bronchial secretion, chlorpheniramine is used for symptomatic relief of allergy, and dextromethorphan is a cough suppressant^{3,4}. The USP HPLC method for its individual assay uses water/ methanol/glacial acetic acid as mobile phase, 4.6 mm×250 mm column packed with L1 10µm, 276 nm detector and 2ml/min rate flow. The retention time is 7 min¹. The USP method for assay of solution three or more of Acetaminophen, Chlorpheniramine Maleate, Dextromethorphan HBr and Pseudoephedrine HCL uses menthol/ water, monobasic potassium phosphate, triethylamine, sodium lauryl sulphate and phosphoric acid as mobile phase. Column 4.6 mm×150 mm, L11, 214 nm detector and

2m/min flow rate¹. Many studies to assay Guaifenesin alone and in combination of other drugs had been done using Spectrophotometric methods HPLC methods and volumetric methods⁵⁻¹⁵. The separation and determination of pseudoephedrine, dextromethorphan, diphenhydramine and chlorpheniramine in cold medicines had been done using Non-aqueous Capillary electrophoresis¹⁶. A HPLC method for simultaneous determination of the four compound plus pyrilamine

and pheniramine had been performed using Kromasil C18 column, mobile phase of methanol and dihydrogen phosphate at pH 3 and wavelength 220 nm, run time of 13 minutes had been achieved¹⁷. The objective is to validate a method for quantitative determination of Pseudoephedrine HCL, Guaifenesin, Chlorpheniramine Maleate and Dextromethorphan HBr simultaneously in one single HPLC injection.

Figure 2: Chromatogram for system suitability.

MATERIALS AND METHODS

Purified water, Blue Nile Research Centre, Sudan. Potassium Dihydrogen Orthophosphate and Acetonitrile HPLC grade, Sharlau Chemie, Spain. Triethanolamine 99.8% AR, Chem lab NV; Belgium. Orthophosphoric acid 88% Luba Chemie. Chlorpheniramine Maleate, Guaifenesin, Dextromethorphan hydrobromide and Pseudoephedrine working standards and test samples. High Performance Liquid Chromatography, Prominence – LC 2030, Shimadzu, Japan. Software Lab solution, Shimadzu, Japan. Column; insert Sustain C18; 4.6 mm× 250 mm; 3 µm. Electronic Balance AY 220, Shimadzu. pH meter Mi 150; Hanna instruments, Romania. Rocking Shaker SK-330-pro, USA. Sonicator 621.05.003 Isolabograde GmpH instruments, Germany.

Chromatographic System

Column: insert Sustain C18; 4.6 mm× 250 mm; 3 µm.

Flow rate: 0.8 ml/min.

Wavelength 210 nm.

Detector: PDA.

Oven temperature: 40°C.

Injection volume: 20 µL.

Run time: 60 min.

Preparation of 0.2 M Potassium dihydrogen orthophosphate: dissolve 27.218 gram in 700 ml water and complete to 1000 ml.

Preparation of mobile phase: to 550 ml of 0.2 M Potassium dihydrogen Orthophosphate in a 1 litre volumetric flask add 200 ml of Acetonitrile, 30 ml of 10% Orthophosphoric acid and 1 ml Triethanolamine 99.8%. Dilute to volume by water and adjust the pH to 3 with orthophosphoric acid or Sodium hydroxide.

Preparation of diluent: use the mobile phase as a diluent. Preparation of the Standard: 100 mg Guaifenesin, 30 mg Pseudoephedrine HCL, 10 mg Dextromethorphan and 2 mg Chlorpheniramine maleate working standards into 100 ml volumetric flask, add 60 diluent, shake and sonicate for 5 minutes, cool and make up to volume with diluent. Mix well, transfer to 10 ml to 50 ml volumetric flask make up to volume with the diluent, mix and filter using 0.45 µL nylon syringe filter. Preparation of the Sample: Transfer 2 ml of the sample of specific gravity 1.2779 g/cm³ = 2.5558 grams to 100 ml volumetric flask, add 60 ml diluent, shake well for 10 minutes, make up to volume with diluent, filter using 0.45 µL nylon syringe filter^{16,17}.

Procedure

Equilibrate the column with mobile phase for sufficient time until stable baseline is obtained. Separately inject equal volumes 20µL of the standard preparation and the assay preparation into the chromatographic system, record the chromatogram and measure the areas of the major peaks.

Table 1: Results of the method Precision.

6 replicates	Pseudoephedrine	Guaifenesin	Chlorpheniramine	Dextromethorphan
Average RT	5.5 mins	12.63 mins	15.85	50.44
RSD%	0.07	0.05	0.08	0.07
Average Area	2850535.33	11585256.33	201544.17	936327
RSD%	0.04	0.04	0.19	0.05
Plates	46780	72286.83	79354	81109.17
Tailing factor	1.38	1.27	1.28	1.23
Peaks resolution	-	20.47	5.6	28.65

Figure 3: The peak purity without interference of Placebo and excipients.

Inject the blank once, the standard solution for 6 replicates and the sample preparation in triplicates. The tailing factor for each peak should not be more than 2 and the RSD should not be more than 2. Calculate the quantity in percentage by the formula:

$$Ru/Rs \times C \times (100/Wu) \times D \times P / 100 \times 1/L \times 100$$

Where, D is the density in mg/ml, W_u is the weight in mg of the sample taken, R_u and R_s are the peak areas responses from the assay preparation and the standard preparation respectively, P is the potency of tested API in % and L is the labeled quantity.

Steps on Method Validation^{18,19}

1. Develop a validation protocol or operating procedure for the validation.
2. Define the application, purpose, and scope of the method.
3. Define the performance parameters and acceptance criteria.

4. Define validation experiments.
5. Verify relevant performance characteristics of equipment.
6. Qualify materials (e.g., standards and reagents).
7. Perform pre-validation experiments.
8. Adjust method parameters or/and acceptance criteria if necessary.
9. Perform full internal (and external) validation experiments.
10. Develop SOPs for executing the method in the routine.
11. Define criteria for revalidation.
12. Define type and frequency of system suitability tests and/or analytical quality control (AQC) checks for the routine.
13. Document validation experiments and results in the validation report.

Table 2: Levels of concentration of Standard µg/ml.

Conc. Level	Pseudoephedrine	Guaifenesin	Chlorpheniramine	Dextromethorphan
1-5%	3 µg/ml	10 µg/ml	0.2 µg/ml	1 µg/ml
2- 10%	6 µg/ml	20 µg/ml	0.4 µg/ml	2 µg/ml
3- 25%	15 µg/ml	50 µg/ml	1 µg/ml	5 µg/ml
4- 50%	30 µg/ml	100 µg/ml	2 µg/ml	10 µg/ml
5- 75%	45 µg/ml	150 µg/ml	3 µg/ml	15 µg/ml
6- 100%	60 µg/ml	200 µg/ml	4 µg/ml	20 µg/ml
7- 125%	75 µg/ml	250 µg/ml	5 µg/ml	25 µg/ml
8- 150%	90 µg/ml	300 µg/ml	6 µg/ml	30 µg/ml
9- 175%	105 µg/ml	350 µg/ml	7 µg/ml	35 µg/ml
10- 200%	120 µg/ml	400 µg/ml	8 µg/ml	40 µg/ml

RESULTS AND DISCUSSION

Precision

The Table 1 presents the average of 6 injection of the standard. The RSD% for the retention times and he

peaks areas of all substances is less than 1%, the theoretical plates is more than 2000, the tailing factors are not more than 2 and the resolution between the

peaks is more than 2. Thus complying, the precision acceptance criteria.

Specificity

Using placebo suspension in the same weight and way of the sample test, following the same procedure, no interference from the placebo was observed at the retention time of the drugs peaks (Figure 3).

Peak purity demonstrates that the observed chromatographic peak is attributed to a single component that the excipients were not interfering with the component peaks at the specific retention time. The acceptance criteria for the peak purity are to be attributed to 90 -100% purity.

Table 3: Peak area and RSD% for linearity.

Level	Pseudoephedrine		Guaifenesin		Chlorpheniramine		Dextromethorphan	
	Area	RSD%	Area	RSD%	Area	RSD%	Area	RSD%
1	164023.3	0.08	709131	0.24	15970.67	0.4	52153.33	0.89
2	302652.3	0.08	1305768	0.06	22415.67	0.54	88761.67	0.38
3	729054.7	0.04	3096022	0.03	54007	0.42	228668.7	0.25
4	1488262	0.15	6191429	0.10	106605	0.38	480969.3	0.77
5	2153761	0.19	8860252	0.31	162422	0.46	704803.7	0.53
6	2853314	0.57	11555520	0.64	218128	0.92	938008	0.82
7	3512556	0.03	14304351	0.02	267495.3	0.33	1159430	0.2
8	4250768	0.88	17240602	0.35	324816	1.0	1402909	0.83
9	4882828	0.04	19679804	0.04	371301	0.16	1613694.7	0.13
10	5535872	0.24	22624204	0.26	427313	0.33	1888020	0.6

Figure 4: Peak Purity of Pseudoephedrine.

Figure 5: Peak Purity of Guaifenesin.

Figure 6: Peak Purity of Chlorpheniramine.

Figure 7: Peak Purity of Dextromethorphan.

Table 4: Linearity Results.

Parameter	Pseudoephedrine	Guaifenesin	Chlorpheniramine	Dextromethorphan
Correlation Coefficient r^2	0.9998	0.9996	0.9997	0.9997
Slope	46098.9590	55897.1449	53117.76	46687.1513
y- intercept	56476.2818	337530.7956	2636.4341	1366.97
Regression line equation	$Y = 46098.959 x + 56476.2818$	$Y = 55897.1449 x + 337530.7956$	$Y = 53117.76 x + 2636.4341$	$Y = 46687.15 x + 1366.97$

Table 5: Results for Accuracy.

Conc	Pseudoephedrine		Guaifenesin		Chlorpheniramine		Dextromethorphan	
	% Mean recovery	RSD %	% Mean recovery	RSD%	% Mean recovery	RSD%	% Mean recovery	RSD%
50%	100.85%	0.11%	100.94	0.01	100.74	0.07	99.71	0.56
100%	100.85%	0.11%	99.43	0.16	100.41	0.16	100.21	0.18
150%	100.83%	0.06%	99.39	0.06	100.73	0.48	100.12	0.19

Table 6: Repeatability Results.

	Pseudoephedrine		Guaifenesin		Chlorpheniramine		Dextromethorphan	
	RT	Area	RT	Area	RT	Area	RT	Area
Mean	5.22	2890773	12.77	11780051	16.23	190932	51.71	179522
RSD%	0.23%	0.2%	0.24%	0.25%	0.44%	0.27%	0.4%	0.19%

Table 7: Results of robustness on change in column temperature.

Variable	Pseudoephedrine				Guaifenesin			
	Mean RT min	Mean area	Theoretical plates	Tailing factor	Mean RT min	Mean area	Theoretical plates	Tailing factor
35°C	5.27	2899252	50442	1.32	13.18	11790008	79212	1.25
RSD%	00	0.08	0.2	0.4	0.03	0.08	0.19	0.14
40°C	5.19	2910793	50395	1.36	12.71	11790008	79086	1.26
RSD%	0.25	0.39	0.55	0.19	0.22	0.8	0.49	0.08
45°C	5.1	2897807	49702	1.42	12.26	11790008	78530	1.26
RSD%	00	0.08	0.2	0.04	0.03	0.08	0.19	0.14
Variable	Chlorpheniramine				Dextromethorphan			
	Mean RT min	Mean area	Theoretical plates	Tailing factor	Mean RT min	Mean area	Theoretical plates	Tailing factor
35°C	17	188365	88614	1.25	55.1	937097	85090	1.22
RSD%	0.04	0.62	0.13	0.23	0.02	0.04	0.23	0.12
40°C	17.51	190058	88982	1.25	51.2	945921	87644	1.22
RSD%	0.4	1.02	0.42	0.14	0.22	0.78	1.11	0.25
45°C	17.88	189603	88894	1.24	47.4	928239	91395	1.21
RSD%	0.14	0.49	0.43	0.12	0.06	0.52	0.28	0.46

Table 8: Resolution of peaks at different temperature.

Column temp	Pseudoephedrine		Guaifenesin		Chlorpheniramine		Dextromethorphan	
	RT	Resolution	RT	Resolution	RT	Resolution	RT	Resolution
35 °C	5.27	-	13.18	21.8	17	7.1	55.1	30
40°C	5.19	-	12.7	21.3	17.5	8.9	51.2	28
55°C	5.1	-	12.3	20.8	17.9	10.5	47.4	26.4

Table 9: Results of Change in the Wavelength.

Variable	Pseudoephedrine				Guaifenesin			
	Mean RT min	Mean area	Theoretical plates	Tailing factor	Mean RT min	Mean area	Theoretical plates	Tailing factor
208 nm	5.22	3165558	51109	1.35	12.78	13490113	75159	1.26
RSD%	0.07	0.3	0.55	00	0.08	0.24	0.2	0.05
210 nm	5.22	2818701	50945	1.35	12.78	11838864	78557	1.25
RSD%	0.07	0.29	0.55	0.04	0.08	0.26	0.02	0.05
112 nm	5.22	2614346	50723	1.35	12.78	10609336	81459	1.25
RSD%	0.07	0.27	0.56	0.04	0.08	0.29	0.03	0.05
Variable	Chlorpheniramine				Dextromethorphan			
	Mean RT min	Mean area	Theoretical plates	Tailing factor	Mean RT min	Mean area	Theoretical plates	Tailing factor
208 nm	17.66	208296	88796	1.25	51.5	1208256	85090	1.22
RSD%	0.13	0.53	0.19	0.09	0.11	0.38	0.23	0.12
210 nm	17.66	189909	88911	1.25	51.5	947748	86680	1.2
RSD%	0.13	0.29	0.2	0.09	0.11	0.37	0.07	0.25
112 nm	17.66	175248	89032	1.25	51.5	748245	86879	1.2
RSD%	0.13	0.4	0.19	0.05	0.1	0.38	0.16	0.13

Table 10: Resolution of peaks at different Wavelengths.

Column temp	Pseudoephedrine		Guaifenesin		Chlorpheniramine		Dextromethorphan	
	RT	Resolution	RT	Resolution	RT	Resolution	RT	Resolution
208 nm	5.2	-	12.8	21	17.7	8.9	51.5	28
210 nm	5.22	-	12.7	21.3	17.6	9	51.5	28
			8		6			
212 nm	5.2	-	12.8	21.5	17.7	9.1	51.5	28

The Peak for Pseudoephedrine is detected at 5.154 min, for Guaifenesin 12.615 min, for Chlorpheniramine 15.83 min and for Dextromethorphan 50.362 min giving rise to peak purity 99.16%, 92.2%, 94.95% and 96.28% as shown in figures 4,5,6,7 respectively.

The acceptance criteria for the correlation Coefficient r^2 should be ≥ 0.999 for the range of concentration 75 –

125% of the target concentration. Thus, the method comply the requirement for linearity.

Range

The data obtained from the accuracy studies may be used to assess the range of the method. 50% to 150% of the target concentration is utilized.

Figure 8: Linearity Chromatograms.

Table 11: Results of robustness on change of flow rate.

Variable	Pseudoephedrine				Guaifenesin			
	Mean RT min	Mean area	Theoretical plates	Tailing factor	Mean RT min	Mean area	Theoretical plates	Tailing factor
0.7 ml/min	5.89	3294494	55188	1.32	14.43	13380124	84056	1.24
RSD%	00	0.07	0.17	0.08	0.01	0.02	0.07	0.05
0.8 ml/min	5.23	2908409	51315	1.35	12.8	11810239	78508	1.25
RSD%	0.05	0.19	0.36	0.13	0.05	0.12	0.1	0.09
0.9 ml/min	4.66	2582571	45811	1.42	11.42	10478534	73876	1.26
RSD%	0.26	0.24	1.1	0.19	0.24	0.26	1.3	0.23
Variable	Chlorpheniramine				Dextromethorphan			
	Mean RT min	Mean area	Theoretical plates	Tailing factor	Mean RT min	Mean area	Theoretical plates	Tailing factor
0.7 ml/min	19.86	213070	93639	1.24	57.9	1067617	90142	1.2
RSD%	0.01	0.11	0.02	0.08	0.02	0.01	0.05	0.22
0.8 ml/min	17.71	189127	89044	1.25	51.6	939955	86973	1.2
RSD%	0.07	0.37	0.07	0.12	0.06	0.37	0.05	0.25
0.9 ml/min	15.75	167279	85353	1.24	4.2	832535	86286	1.22
RSD%	0.45	0.31	0.71	0.08	0.21	0.05	0.86	0.28

Table 12: Resolution of peaks in changing the rate flow.

Flow rate	Pseudoephedrine		Guaifenesin		Chlorpheniramine		Dextromethorphan	
	RT	Resolution	RT	Resolution	RT	Resolution	RT	Resolution
0.7 ml/min	5.9	-	14.4	22.1	19.9	9.2	57.9	28.6
0.8 ml/min	5.2	-	12.8	21.4	17.7	9	51.6	28
0.9 ml/min	5.2	-	12.8	20.5	17.7	8.8	51.5	27.9

Table 13: The average and RSD% of peak areas for solution stability.

Parameter	Pseudoephedrine	Guaifenesin	Chlorpheniramine	Dextromethorphan
Mean peaks areas	2879033	11675642	187949	98897
RSD%	0.12	0.19	0.15	0.48

Limit of detection DL and limit of quantitation QL

$$DL = 3.3 \times \frac{MRSE}{Slope} \quad QL = 10 \times \frac{MRSE}{Slope}$$

MRSE = Mean Root Square Error,

DL µg/ml: 2.67, 10, 0.15, 0.86 for Pseudoephedrine, Guaifenesin, Chlorpheniramine, Dextromethorphan respectively. QL µg/ml: 8.08, 31.14, 0.47, 2.6^{14,15}.

Accuracy

According to the ICH guide lines Q2 the accuracy is assessed using three replicates of each of the concentrations 50%, 100% and 150% were analyzed for theoretical values, RSD and percent recovery. Since the acceptance criteria is that the measured recovery should be 95%- 105%, so the method comply the requirement for accuracy^{16,17}.

Precision**Repeatability**

10 replicates of the sample were used and the mean, stand deviation and relative standard deviation were obtained. The FDA and ICH stated that the RSD should be ± 1% for the drug substance and ± 2% for the drug product. Thus, the method fulfilled the repeatability criterion.

Intermediate Precision

Intermediate precision within laboratory variations had been demonstrated by two analysts, using two HPLC systems on different days and evaluating the relative percent purity data across the two HPLC systems at three concentration levels; 50%, 100% and 150%. The following results were obtained: S₁A and S₁B is the RSD% of concentration 50% for analysts A and B. S₂A and S₂B is the RSD% of concentration 100% for analysts A and B. S₃A and S₃B is the RSD% of concentration 150% for analysts A and B. Two different systems at two different days technique were used. S₂a + S₂b are 0.52, 0.27, 0.09, and 0.17 for the four compounds respectively. S₃a + S₃b are 0.97, 1.0, 0.34, and 0.21 for the four compounds respectively. Since the acceptance criterion for intermediate precision is that the results obtained by two analysts using two instruments at different days should have statistical RSD ≤ 2%, thus the method comply the acceptable criteria²⁰.

Robustness**Effect of change in column temperature**

Acceptance Criteria for Robustness

1. The number of the theoretical plates should be less than 2000.
2. The tailing factor for compounds should not be more than 2.0.
3. The RSD% of the peaks areas of the replicates of either the standard solution or the compounds should not be more than 2.0%.
4. The resolution between the peaks of the compounds should be ≥ 2.0.

The method fulfilled the acceptance criteria as the number of the theoretical plates in all variables is more than 2000, the RSD% of the retention time and peaks

area are less than 2.0%, the tailing factor for all peaks of the different variables are less than 2.0 and the resolution between the peaks is more than 2.0.

Thus, the method satisfied the requirements for robustness on changing the column temperature, on changing the detection wavelength and on changing the flow rate.

Solution Stability

The test had been carried out by initial testing then after preservation of the test solution for 6 hours, 12 hours, 18 hours, 24 hours and 48 hours. The RSD% for the peaks areas of all compounds is less than 2%, therefore, the standard preparation is stable for 48 hours at room temperature.

CONCLUSION

The analytical method used for determination of Pseudoephedrine HCL, Guaifenesin, Chlorpheniramine Maleate and Dextromethorphan HBr in syrup as four-in-one was found to be consistent and precise and in conformance with the acceptable criteria of validation parameters of specificity, system suitability, linearity and range, precision, accuracy, reproducibility and robustness. The method is fully validated and can be used in routine testing for simultaneous determination of such combination products.

ACKNOWLEDGEMENTS

The team and manager of Blue Nile Research Centre were greatly acknowledged for their great support and encouragement.

AUTHOR'S CONTRIBUTION

The manuscript was carried out, written, and approved in collaboration with all authors.

CONFLICT OF INTEREST

No conflict of interest associated with this work.

REFERENCES

1. United States Pharmacopeia 2013; USP 39 - The National Formulary, 1/5/2016, 12601 Twinbrook Parkway, Rockville, MD 20852, USP Volume 1 p 1641, volume 2, 2310, 4164 volume 2. (tablet containing at least three of the following-acetaminophen, chlorpheniramine, dextromethorphan and pseudoephedrine. <https://doi.org/10.1002/jps.2600740943>
2. ICH Q2 validation of analytical procedures Part 2, 6/1995, ICH, Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products, 2003., www.emea.eu.int
3. Wikipedia, <http://www.en.wikipedia.org> 25/10/2020, 13:00

4. British National Formulary 80, September 2020, Royal Pharmaceutical Society, published by BMI Group and Pharmaceutical Press, 221.
5. Acharya P, Kumar TP, Agasteen I, *et al.* A review on analytical methods for determination of guaifenesin alone and in combination with other drugs in pharmaceutical formulation. Saudi J Med Pharm Sci 2017., <https://doi.org/10.21276/sjmps.2017.3.3.7>
6. Bhattacharyya I, Bhattacharyya SP, Kyal C, *et al.* Estimation and validation of stability indicating UV spectrophotometric method for the determination of Guaifenesin in presence of its degradant products. Int J Pharm Pharm Sci 2013; 5(1): 262-268.
7. Chavan RS, Arale SS, Akmar NR. Development and validation of UV spectrophotometric area under curve method for estimation of Guaifenesin in bulk and tablet dosage form. Inventi 2014; 1535.
8. Reddy SP, Babu SK, Kumar N, Sasi Sekhar YVV. Development and validation of stability indicating the RP-HPLC method for the estimation of related compounds of Guaifenesin in pharmaceutical dosage forms. Pharm Methods 2011; 2(4): 229-234. <https://doi.org/10.4103/2229-4708.93391>
9. Tapsoba I, Belgaied JE, Boujlel K. Voltammetric assay of Guaifenesin in pharmaceutical formulation. J Pharm Biomed Analysis 2005; 38: 162–165. <https://doi.org/10.1016/j.jpba.2004.11.056>
10. Maged HM Sharaf, Dwight D Stiff. Determination of guaifenesin in human serum by capillary gas chromatography and electron capture detection. J Pharm Biomed Analysis 2004; 35: 801–806. <https://doi.org/10.1016/j.jpba.2004.01.028>
11. Asirvatham AA, Manikandan K, Mailvelan R, Kishore Konam, Rajavel P. Estimation of Guaifenesin in human plasma by liquid chromatography coupled with tandem mass spectroscopy. Int J Bio Pharm Res 2012, 3(3), 463-468.
12. Banker AA, Lokhande SR, Sawant RL, Bhagat AR. Spectrophotometric estimation of Guaifenesin and Salbutamol in pure and tablet dosage form by using different methods. Scholars Res Lib 2013; 5(3): 92-97.
13. R Vani, M Sunitha. Analytical method development and validation for the determination of Omeprazole and Aspirin using reverse phase HPLC method in bulk and dosage form. Universal J Pharm Res 2017; 2(4): 25-28. <https://doi.org/10.22270/ujpr.v2i4.R6>
14. Abdallah OM. Sensitive Spectrophotometric method for quantitation of guaifenesin and dropripizine in their dosage forms. Int J Ana Chem 2010; Article ID 704564. <https://doi.org/10.1155/2010/704564>
15. Pushpalatha E, Tejaswini P, Niboon M, *et al.* Development of UV spectroscopic determination of Guaifenesin in bulk and formulation. Int J Pharm Res Ana 2015; 5(2): 90-95.
16. Sahu Rahul S, Kumar SH, Sahu V, *et al.* Spectrophotometric determination of guaifenesin and pseudoephedrine hydrochloride in tablet dosage form. Int J Res Pharm Sci 2011; 1(3): 41-49.
17. Dong Y, Xiaofeng C, Yonglei C, Xingguo C, Zhide H, Separation and determination of pseudoephedrine, dextromethorphan, diphenhydramine and Chlorpheniramine in cold medicines by no aqueous capillary electrophoresis. J Pharm Biomed Anal 2005; 39:285-9. <https://doi.org/10.1016/j.jpba.2005.02.032>
18. Shahul Hameed M, Jat RK, Indulatha VN. Validation of HPLC and UV visible methods for few selected blood pressure lowering drugs and their formulations. Universal J Pharm Res 2017; 2(1): 25-29. <https://doi.org/10.22270/ujpr.v2i1.R6>
19. Mohamed L, Jebali S, Mohamed L, Nafaa A. Simultaneous determination of pseudoephedrine, pheniramine, guaifensin, pyrilamine, chlorpheniramine and dextromethorphan in cough and cold medicines by high performance liquid chromatography. Talanta 2009; 78(3): 991-7. <https://doi.org/10.1016/j.talanta.2009.01.019>
20. BESKAN U, TUNA YILDIRIM S, ALGIN YAPAR E. An overview of analytical method validation. Universal J Pharm Res 2020; 5(1): 47-52. <https://doi.org/10.22270/ujpr.v5i1.362>